Percutaneous coronary intervention saphenous vein grafts
Jump to navigation
Jump to search
|
Percutaneous Coronary Intervention Guidelines Microchapters |
|
PCI Approaches: |
|---|
|
CAD Revascularization: |
|
Pre-procedural Considerations: |
|
Procedural Considerations: |
|
|
|
|
|
|
|
|
|
|
Post-Procedural Considerations: |
|
Quality and Performance Considerations: |
|
Percutaneous coronary intervention saphenous vein grafts On the Web |
|
American Roentgen Ray Society Images of Percutaneous coronary intervention saphenous vein grafts |
|
FDA on Percutaneous coronary intervention saphenous vein grafts |
|
CDC on Percutaneous coronary intervention saphenous vein grafts |
|
Percutaneous coronary intervention saphenous vein grafts in the news |
|
Blogs on Percutaneous coronary intervention saphenous vein grafts |
|
Directions to Hospitals Treating Percutaneous Coronary Intervention |
|
Risk calculators and risk factors for Percutaneous coronary intervention saphenous vein grafts |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)[1]
Saphenous Vein Grafts (DO NOT EDIT)[1]
| Class I |
| "1. Embolic protection devices should be used during saphenous vein graft PCI when technically feasible.[2][3][4][5] (Level of Evidence: B)" |
| Class III (No Benefit) |
| "1. Platelet GP IIb/IIIa inhibitors are not beneficial as adjunctive therapy during saphenous vein graft PCI.[6][7][8][9](Level of Evidence: B)" |
| Class III (Harm) |
| "1. PCI is not recommended for chronic saphenous vein graft occlusions.[10][11][12](Level of Evidence: C)" |
References
- ↑ 1.0 1.1 Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions" (PDF). Journal of the American College of Cardiology. 58 (24): 2550–83. doi:10.1016/j.jacc.2011.08.006. PMID 22070837. Retrieved 2011-12-08. Text "PDF" ignored (help); Unknown parameter
|month=ignored (help) - ↑ Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE (2002). "Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts". Circulation. 105 (11): 1285–90. PMID 11901037. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Coolong A, Baim DS, Kuntz RE, O'Malley AJ, Marulkar S, Cutlip DE, Popma JJ, Mauri L (2008). "Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients". Circulation. 117 (6): 790–7. doi:10.1161/CIRCULATIONAHA.106.651232. PMID 18212287. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Mauri L, Cox D, Hermiller J, Massaro J, Wahr J, Tay SW, Jonas M, Popma JJ, Pavliska J, Wahr D, Rogers C (2007). "The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial". Journal of the American College of Cardiology. 50 (15): 1442–9. doi:10.1016/j.jacc.2007.06.039. PMID 17919563. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA (2003). "Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts". Circulation. 108 (5): 548–53. doi:10.1161/01.CIR.0000080894.51311.0A. PMID 12874191. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM (2007). "Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation". JAMA : the Journal of the American Medical Association. 297 (2): 159–68. doi:10.1001/jama.297.2.joc60179. PMID 17148711. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Brar SS, Kim J, Brar SK, Zadegan R, Ree M, Liu IL, Mansukhani P, Aharonian V, Hyett R, Shen AY (2008). "Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions". Journal of the American College of Cardiology. 51 (23): 2220–7. doi:10.1016/j.jacc.2008.01.063. PMID 18534267. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol EJ (2002). "Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials". Circulation. 106 (24): 3063–7. PMID 12473552. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Ellis SG, Lincoff AM, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, Califf R, Topol EJ (1998). "Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade". Journal of the American College of Cardiology. 32 (6): 1619–23. PMID 9822087. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Al-Lamee R, Ielasi A, Latib A, Godino C, Ferraro M, Arioli F, Mussardo M, Piraino D, Figini F, Carlino M, Montorfano M, Chieffo A, Colombo A (2010). "Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques". The American Journal of Cardiology. 106 (12): 1721–7. doi:10.1016/j.amjcard.2010.08.013. PMID 21126616. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ de Feyter PJ, Serruys P, van den Brand M, Meester H, Beatt K, Suryapranata H (1989). "Percutaneous transluminal angioplasty of a totally occluded venous bypass graft: a challenge that should be resisted". The American Journal of Cardiology. 64 (1): 88–90. PMID 2525867. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ de Feyter PJ, van Suylen RJ, de Jaegere PP, Topol EJ, Serruys PW (1993). "Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts". Journal of the American College of Cardiology. 21 (7): 1539–49. PMID 8496517. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help)